Skip to main content
Top
Published in: Rheumatology International 4/2016

01-04-2016 | Original Article - Biomarkers

Association between high-sensitivity C-reactive protein and hyperuricemia

Authors: Tuo Yang, Xiang Ding, Yi-lun Wang, Chao Zeng, Jie Wei, Hui Li, Yi-lin Xiong, Shu-guang Gao, Yu-sheng Li, Guang-hua Lei

Published in: Rheumatology International | Issue 4/2016

Login to get access

Abstract

The aim of the study was to examine the cross-sectional association between high-sensitivity C-reactive protein (hsCRP) and hyperuricemia (HU). The hsCRP was measured by latex turbidity method. Uric acid was detected on Beckman Coulter AU 5800. HU was defined as uric acid ≥416 μmol/L for the male population and ≥360 μmol/L for the female population. A multivariable logistic analysis model was applied to test the association after adjusting for a number of potential confounding factors. A total of 1935 subjects were included in this study. According to the multivariable regression model, the relative odds of the prevalence of HU were increased by 0.56 times in the third quintile (OR 1.56, 95 % CI 1.03–2.38, P = 0.04), 0.55 times in the fourth quintile (OR 1.55, 95 % CI 1.01–2.36, P = 0.04) and 0.96 times in the fifth quintile (OR 1.96, 95 % CI 1.29–2.98, P < 0.01) of hsCRP comparing with the lowest quintile, and P for trend was smaller than 0.01. In the male population, a positive association existed in the highest quintile of hsCRP (OR 1.66, 95 % CI 1.04–2.66, P = 0.04), and P for trend was 0.07. In the female population, the multivariable-adjusted ORs (95 % CI) of HU in the fourth and fifth quintile of hsCRP were 3.02 (95 % CI 1.09–8.35, P = 0.03) and 3.66 (95 % CI 1.36–9.89, P = 0.01), respectively, and P for trend was smaller than 0.01. The findings of this cross-sectional study suggest that the hsCRP level is positively associated with the prevalence of HU.
Level of evidence Cross-sectional study, Level III.
Literature
1.
go back to reference Sluijs I, Beulens JW, van der A DL et al (2013) Plasma uric acid is associated with increased risk of type 2 diabetes independent of diet and metabolic risk factors. J Nutr 143(1):80–85CrossRefPubMed Sluijs I, Beulens JW, van der A DL et al (2013) Plasma uric acid is associated with increased risk of type 2 diabetes independent of diet and metabolic risk factors. J Nutr 143(1):80–85CrossRefPubMed
2.
go back to reference Filiopoulos V, Hadjiyannakos D, Vlassopoulos D (2012) New insights into uric acid effects on the progression and prognosis of chronic kidney disease. Ren Fail 34(4):510–520CrossRefPubMed Filiopoulos V, Hadjiyannakos D, Vlassopoulos D (2012) New insights into uric acid effects on the progression and prognosis of chronic kidney disease. Ren Fail 34(4):510–520CrossRefPubMed
4.
go back to reference Puddu P, Puddu GM, Cravero E et al (2012) The relationships among hyperuricemia, endothelial dysfunction, and cardiovascular diseases: molecular mechanisms and clinical implications. J Cardiol 59(3):235–242CrossRefPubMed Puddu P, Puddu GM, Cravero E et al (2012) The relationships among hyperuricemia, endothelial dysfunction, and cardiovascular diseases: molecular mechanisms and clinical implications. J Cardiol 59(3):235–242CrossRefPubMed
8.
go back to reference Meng ZH, Hudson AP, Schumacher HR Jr et al (1997) Monosodium urate, hydroxyapatite, and calcium pyrophosphate crystals induce tumour necrosis factor-alpha expression in a mononuclear cell line. J Rheumatol 24(12):2385–2388PubMed Meng ZH, Hudson AP, Schumacher HR Jr et al (1997) Monosodium urate, hydroxyapatite, and calcium pyrophosphate crystals induce tumour necrosis factor-alpha expression in a mononuclear cell line. J Rheumatol 24(12):2385–2388PubMed
9.
go back to reference Lyngdoh T, Marques-Vidal P, Paccaud F et al (2011) Elevated serum uric acid is associated with high circulating inflammatory cytokines in the population-based Colaus study. PLoS ONE 6(5):e19901CrossRefPubMedPubMedCentral Lyngdoh T, Marques-Vidal P, Paccaud F et al (2011) Elevated serum uric acid is associated with high circulating inflammatory cytokines in the population-based Colaus study. PLoS ONE 6(5):e19901CrossRefPubMedPubMedCentral
10.
go back to reference Kirilmaz B, Asgun F, Alioglu E et al (2010) High inflammatory activity related to the number of metabolic syndrome components. J Clin Hypertens (Greenwich) 12(2):136–144CrossRef Kirilmaz B, Asgun F, Alioglu E et al (2010) High inflammatory activity related to the number of metabolic syndrome components. J Clin Hypertens (Greenwich) 12(2):136–144CrossRef
11.
go back to reference Campion EW, Glynn RJ, DeLabry LO (1987) Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med 82(3):421–426CrossRefPubMed Campion EW, Glynn RJ, DeLabry LO (1987) Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med 82(3):421–426CrossRefPubMed
12.
go back to reference Lin KC, Lin HY, Chou P (2000) The interaction between uric acid level and other risk factors on the development of gout among asymptomatic hyperuricemic men in a prospective study. J Rheumatol 27(6):1501–1505PubMed Lin KC, Lin HY, Chou P (2000) The interaction between uric acid level and other risk factors on the development of gout among asymptomatic hyperuricemic men in a prospective study. J Rheumatol 27(6):1501–1505PubMed
14.
go back to reference Ho WJ, Tsai WP, Yu KH et al (2010) Association between endothelial dysfunction and hyperuricaemia. Rheumatology 49(10):1929–1934CrossRefPubMed Ho WJ, Tsai WP, Yu KH et al (2010) Association between endothelial dysfunction and hyperuricaemia. Rheumatology 49(10):1929–1934CrossRefPubMed
15.
go back to reference Mutluay R, Deger SM, Bahadir E et al (2012) Uric acid is an important predictor for hypertensive early atherosclerosis. Adv Ther 29(3):276–286CrossRefPubMed Mutluay R, Deger SM, Bahadir E et al (2012) Uric acid is an important predictor for hypertensive early atherosclerosis. Adv Ther 29(3):276–286CrossRefPubMed
16.
go back to reference Wasilewska A, Tenderenda E, Taranta-Janusz K et al (2012) Markers of systemic inflammation in children with hyperuricemia. Acta Paediatr 101(5):497–500CrossRefPubMed Wasilewska A, Tenderenda E, Taranta-Janusz K et al (2012) Markers of systemic inflammation in children with hyperuricemia. Acta Paediatr 101(5):497–500CrossRefPubMed
17.
go back to reference Ryu S, Chang Y, Zhang Y et al (2012) A cohort study of hyperuricemia in middle-aged South Korean men. Am J Epidemiol 175(2):133–143CrossRefPubMed Ryu S, Chang Y, Zhang Y et al (2012) A cohort study of hyperuricemia in middle-aged South Korean men. Am J Epidemiol 175(2):133–143CrossRefPubMed
18.
go back to reference Zeng C, Wang YL, Wei J et al (2015) Association between low serum magnesium concentration and hyperuricemia. Magnes Res 28(2):56–63PubMed Zeng C, Wang YL, Wei J et al (2015) Association between low serum magnesium concentration and hyperuricemia. Magnes Res 28(2):56–63PubMed
19.
go back to reference Zeng C, Wei J, Li H et al (2015) Relationship between serum magnesium concentration and radiographic knee osteoarthritis. J Rheumatol 42(7):1231–1236CrossRefPubMed Zeng C, Wei J, Li H et al (2015) Relationship between serum magnesium concentration and radiographic knee osteoarthritis. J Rheumatol 42(7):1231–1236CrossRefPubMed
21.
go back to reference Mora S, Rifai N, Buring JE et al (2006) Additive value of immunoassay-measured fibrinogen and high-sensitivity C-reactive protein levels for predicting incident cardiovascular events. Circulation 114(5):381–387CrossRefPubMed Mora S, Rifai N, Buring JE et al (2006) Additive value of immunoassay-measured fibrinogen and high-sensitivity C-reactive protein levels for predicting incident cardiovascular events. Circulation 114(5):381–387CrossRefPubMed
22.
go back to reference Hayashino Y, Mashitani T, Tsujii S et al (2014) Elevated levels of hs-CRP are associated with high prevalence of depression in japanese patients with type 2 diabetes: the Diabetes Distress and Care Registry at Tenri (DDCRT 6). Diabetes Care 37(9):2459–2465CrossRefPubMed Hayashino Y, Mashitani T, Tsujii S et al (2014) Elevated levels of hs-CRP are associated with high prevalence of depression in japanese patients with type 2 diabetes: the Diabetes Distress and Care Registry at Tenri (DDCRT 6). Diabetes Care 37(9):2459–2465CrossRefPubMed
23.
go back to reference Friedman AN, Hunsicker LG, Selhub J et al (2005) C-reactive protein as a predictor of total arteriosclerotic outcomes in type 2 diabetic nephropathy. Kidney Int 68(2):773–778CrossRefPubMed Friedman AN, Hunsicker LG, Selhub J et al (2005) C-reactive protein as a predictor of total arteriosclerotic outcomes in type 2 diabetic nephropathy. Kidney Int 68(2):773–778CrossRefPubMed
24.
go back to reference Bo S, Durazzo M, Guidi S et al (2006) Dietary magnesium and fiber intakes and inflammatory and metabolic indicators in middle-aged subjects from a population-based cohort. Am J Clin Nutr 84:1062–1069PubMed Bo S, Durazzo M, Guidi S et al (2006) Dietary magnesium and fiber intakes and inflammatory and metabolic indicators in middle-aged subjects from a population-based cohort. Am J Clin Nutr 84:1062–1069PubMed
25.
go back to reference King DE, Mainous AR, Geesey ME et al (2005) Dietary magnesium and C-reactive protein levels. J Am Coll Nutr 24:166–171CrossRefPubMed King DE, Mainous AR, Geesey ME et al (2005) Dietary magnesium and C-reactive protein levels. J Am Coll Nutr 24:166–171CrossRefPubMed
26.
go back to reference Kang DH, Park SK, Lee IK et al (2005) Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol 16(12):3553–3562CrossRefPubMed Kang DH, Park SK, Lee IK et al (2005) Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol 16(12):3553–3562CrossRefPubMed
27.
go back to reference Khalil RA (2013) Estrogen, vascular estrogen receptor and hormone therapy in postmenopausal vascular disease. Biochem Pharmacol 86(12):1627–1642CrossRefPubMed Khalil RA (2013) Estrogen, vascular estrogen receptor and hormone therapy in postmenopausal vascular disease. Biochem Pharmacol 86(12):1627–1642CrossRefPubMed
28.
go back to reference Martinon F, Pétrilli V, Mayor A et al (2006) Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440(7081):237–241CrossRefPubMed Martinon F, Pétrilli V, Mayor A et al (2006) Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440(7081):237–241CrossRefPubMed
29.
go back to reference Martinon F, Tschopp J (2004) Inflammatory caspases: linking an intracellular innate immune system to autoinflammatory diseases. Cell 117:561–574CrossRefPubMed Martinon F, Tschopp J (2004) Inflammatory caspases: linking an intracellular innate immune system to autoinflammatory diseases. Cell 117:561–574CrossRefPubMed
31.
32.
go back to reference Roberts WL, Moulton L, Law TC et al (2001) Evaluation of nine automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications. Part 2. Clin Chem 47(3):418–425PubMed Roberts WL, Moulton L, Law TC et al (2001) Evaluation of nine automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications. Part 2. Clin Chem 47(3):418–425PubMed
Metadata
Title
Association between high-sensitivity C-reactive protein and hyperuricemia
Authors
Tuo Yang
Xiang Ding
Yi-lun Wang
Chao Zeng
Jie Wei
Hui Li
Yi-lin Xiong
Shu-guang Gao
Yu-sheng Li
Guang-hua Lei
Publication date
01-04-2016
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 4/2016
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-016-3429-z

Other articles of this Issue 4/2016

Rheumatology International 4/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.